Literature DB >> 9140633

Ocular abnormalities in chronic schizophrenia: clinical implications.

D Smith1, C Pantelis, J McGrath, C Tangas, D Copolov.   

Abstract

OBJECTIVE: As part of a randomised double-blind study of a new atypical antipsychotic we sought to determine both the levels of visual acuity and the occurrence of toxic side-effects in a group of patients treated for many years on a variety of antipsychotics.
METHODS: Twenty-three inpatients with a DSM-III-R diagnosis of chronic schizophrenia from two separate hospital locations who met the criteria for the double-blind trial were examined for ocular abnormalities at both baseline and at trial completion.
RESULTS: At baseline a high prevalence of abnormalities was identified: 19 patients (82.6%) were found to have one or more ocular abnormalities, including lens opacities/cataracts and corneal pigmentation; three patients, with delusions related to the sun, were noted to have solar burns; a high proportion (almost 70%) of patients had untreated visual acuity problems. No further changes were observed at the follow-up examinations.
CONCLUSIONS: The possible causes of ocular disturbance in schizophrenia and the reasons for the relatively high ocular morbidity in this group are thought to result from both illness-related factors and the effects of antipsychotic medication. Causality is confounded by a number of issues such as the high prevalence of smoking, poor general health and the variety of antipsychotic medications used in the treatment of psychosis as well as substance abuse. The clinical implications are considered in this paper in relation to the move towards community-based psychiatric services.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9140633     DOI: 10.3109/00048679709073828

Source DB:  PubMed          Journal:  Aust N Z J Psychiatry        ISSN: 0004-8674            Impact factor:   5.744


  9 in total

1.  Prevalence of diagnosed ocular disease in veterans with serious mental illness.

Authors:  Osamah Saeedi; Hasan Ashraf; Marc Malouf; Eric P Slade; Deborah R Medoff; Lan Li; Julie Kreyenbuhl
Journal:  Gen Hosp Psychiatry       Date:  2016-08-18       Impact factor: 3.238

Review 2.  Quetiapine: a review of its safety in the management of schizophrenia.

Authors:  V Dev; J Raniwalla
Journal:  Drug Saf       Date:  2000-10       Impact factor: 5.606

3.  Schizophrenia as segmental progeria.

Authors:  Evangelos Papanastasiou; Fiona Gaughran; Shubulade Smith
Journal:  J R Soc Med       Date:  2011-11       Impact factor: 5.344

4.  Visual perceptual remediation for individuals with schizophrenia: Rationale, method, and three case studies.

Authors:  Pamela D Butler; Judy L Thompson; Aaron R Seitz; Jenni Deveau; Steven M Silverstein
Journal:  Psychiatr Rehabil J       Date:  2016-08-22

5.  Visual impairment in persons with psychotic disorder.

Authors:  Satu Viertiö; Arja Laitinen; Jonna Perälä; Samuli I Saarni; Seppo Koskinen; Jouko Lönnqvist; Jaana Suvisaari
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2007-09-10       Impact factor: 4.328

6.  Computational Modeling of Contrast Sensitivity and Orientation Tuning in First-Episode and Chronic Schizophrenia.

Authors:  Steven M Silverstein; Docia L Demmin; James A Bednar
Journal:  Comput Psychiatr       Date:  2017-12-01

7.  Schizophrenia and the eye.

Authors:  Steven M Silverstein; Richard Rosen
Journal:  Schizophr Res Cogn       Date:  2015-06

8.  Processing of spatial-frequency altered faces in schizophrenia: effects of illness phase and duration.

Authors:  Steven M Silverstein; Brian P Keane; Thomas V Papathomas; Kira L Lathrop; Hristian Kourtev; Keith Feigenson; Matthew W Roché; Yushi Wang; Deepthi Mikkilineni; Danielle Paterno
Journal:  PLoS One       Date:  2014-12-08       Impact factor: 3.240

Review 9.  Anesthesia Considerations for Cataract Surgery in Patients with Schizophrenia: A Narrative Review.

Authors:  Chandra M Kumar; Howard D Palte; Alfred W Y Chua; Renu Sinha; Shreya B Shah; Farnad Imani; Zahra M Jalali
Journal:  Anesth Pain Med       Date:  2021-04-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.